Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer

Clinical Colorectal Cancer

Volumn 4, Issue 1, 2004, Pages 51-62

  Amador, Maria L ^a   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cetuximab; Erlotinib; Gefitinib; Irinotecan; Monoclonal antibody

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; CANERTINIB; CARBOPLATIN; CETUXIMAB; CHIMERIC ANTIBODY; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; ORTATAXEL; PACLITAXEL; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TOPOTECAN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BONE MARROW TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONJUNCTIVITIS; CORNEA EROSION; DIARRHEA; DOWNSTREAM PROCESSING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; PROGNOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

EID: 3042661007     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.010     Document Type: Article

References (125)

1. Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Skibber J, Minsky B, Hoff P. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippipcott Willians & Wilkins, 2001:1216-1270.
3. Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 2002; 26:109-164.
4. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203-212.
5. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-S8.
6. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-3167.
7. Radinsky R, Risin, Fan, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.
8. Solic N, Davies DE. Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells. Exp Cell Res 1997; 234:465-476.
9. Damstrup L, Kuwada SK, Dempsey PJ, et al. Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 1999; 80:1012-1019.
10. Yang H, Jiang D, Li W, et al. Defective cleavage of membrane bound TGFalpha leads to enhanced activation of the EGF receptor in malignant cells. Oncogene 2000; 19:1901-1914.
11. Normanno N, De Luca A, Salomon DS, et al. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. Cancer Detect Prev 1998; 22:62-67.
12. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
13. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37:285-289.
14. Coffey RJ, Jr., Graves-Deal R, Dempsey PJ, et al. Differential regulation of transforming growth factor alpha autoinduction in a nontransformed and transformed epithelial cell. Cell Growth Differ 1992; 3:347-354.
15. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol 1990; 416:343-349.
16. Prewett M, Hooper A, Bassi R, et al. Growth of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody in combination with 5-fluorouracil or irinotecan. Proc Am Assoc Cancer Res 2001; 42:287 (Abstract #1543).
17. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988; 48:137-141.
18. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
19. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995; 14:323-338.
20. Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002; 38:1065-1071.
21. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565.
22. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
23. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37(suppl 4):S16-S22.
24. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-1530.
25. Aboud-Pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988; 80:1605-1611.
26. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259:7755-7760.
27. Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983; 80:1337-1341.
28. Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1:511-529.
29. Kang X, Patel D, Shi J, et al. Anti-EGFR monoclonal antibody Cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface. Eur J Cancer 2002; 38(suppl 7): S149 (Abstract #498).
30. Fan Z, Shang BY, Lu Y, et al. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 1997; 3:1943-1948.
31. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56:3666-3669.
32. Mandal M, Adam L, Mendelsohn J, et al. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998; 17:999-1007.
33. Liu B, Fang M, Schmidt M, et al. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82:1991-1999.
34. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
35. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-265.
36. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936-1948.
37. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-1318.
38. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002-1007.
39. Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
40. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-4642.
41. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5:909-916.
42. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001; 19(suppl):41S-44S.
43. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
44. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8: 1253-1264.
45. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000; 6:4343-4350.
46. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001; 11:281-289.
47. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6:2166-2174.
48. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
49. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18:731-738.
50. Ciardiello F, Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 1998; 4:821-828.
51. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
52. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7:1204-1213.
53. Mendelsohn J, Shin DM, Donato N, et al. A phase I study of chimerized ant-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). Proc Am Soc Clin Oncol 1999; 18:398a (Abstract #1502).
54. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243.
55. Saltz L, Meropol N, Loehrer P, et al. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer that expresses the epidermal growth factor receptor(EGFR). Proc Am Soc Clin Oncol 2002; 21:127a (Abstract #504).
56. Saltz L, Rubin M, Hochster J, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that express epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
57. Rosenberg A, Loehrer P, Needle M, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor. Proc Am Soc Clin Oncol 2002; 21:135a (Abstract #536).
58. Schoffski P, Lutz CH, Folprecht G, et al. Cetuximab (C225, Erbitux) in combination with irinotecan, infusional fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Eur J Cancer 2002; 38(suppl 7):S148 (Abstract #495).
59. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
60. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-1243.
61. Figlin R, Belldegrun AS., Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 2002; 21:11a (Abstract #35).
62. Bier H, Hoffmann T, Haas I, et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46:167-173.
63. Hoffmann T, Hafner D, Ballo H, et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 1997; 17:4419-4425.
64. Modjtahedi H, Eccles S, Sandle J, et al. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 1994; 54:1695-1701.
65. Sturgis EM, Sacks PG, Masui H, et al. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol Head Neck Surg 1994; 111:633-643.
66. Hambek M, Solbach C, Schnuerch HG, et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001; 61:1045-1049.
67. Schleucher N, Tewes, M, Dirsch, O. et al. Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors. Eur J Cancer 2002; 38(suppl 7):S53 (Abstract #164).
68. Tabernero J, Rojo F, Jimenez E, et al. A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:192 (Abstract #770).
69. Bier H, Hoffmann T, Hauser U, et al. Clinical tril with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001; 47:519-524.
70. Crombet-Ramos T, Rak J, Perez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-575.
71. Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81.
72. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-5101.
73. Barker A, Gibson K, Grundy W, et al. Studies leading to the identification of ZD 1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem 2001; 11: 1911-1914.
74. Woodburn J, Kendrew J, Fennell M, et al. Zd 1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumour growth inhibition. Proc Am Assoc Cancer Res 2000; 41:402 (Abstract #2552).
75. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
76. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774-782.
77. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7:145971465.
78. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60(suppl 1):33-40.
79. Di Gennaro E, Marcella F, Bruzzese F, et al. Growth inhibition of tumour cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors. Clin Cancer Res 1999; 5(suppl):S10 (Abstract #118).
80. Chan K, Knox WF, Ghandi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epitherlial proliferation. Br J Surg 2001; 88:412-418.
81. Hutcheson I, Gee J, Barrow D, et al. Endocrine resitance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Presented at: Signal transduction pathways and regulation of gene expression as therapeutic targets; January 30 to February 2, 2002; Kirchberg, Luxembourg.
82. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
83. Woodburn J, Barker A, Wakeling A, et al. 6-Amino-4-(3-methyuphenylamino)-quinazoline: an EGF receptor tirosine kinase inhibitor - with activity in a range of human tumor xenografts. Proc Am Assoc Cancer Res 1996; 37:390-391.
84. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
85. Williams KJ, Telfer BA, Stratford IJ, et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86:1157-1161.
86. Moulder SL, Yakes M Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61:8887-8895.
87. Normanno N, Campiglio M, De LA, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65-72.
88. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99:1521-1526.
89. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
90. Tortora G, Caputo R, Damiano V, et al. Specif inhibition of EGFR tirosine kinase with ZD 1839 ('Iressa') combined with protein kinase A antisense and the novel taxane IDN5109 causes cooperative inhibition of tumour growth and angiogenesis. Proc Am Assoc Cancer Res 2001; 43:804 (Abstract #4315).
91. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19:177a (Abstract #686).
92. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
93. Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a phase I intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 2001; 20:324a (Abstract #1292).
94. Goss G, Hirte H, Lorimer I, et al. Final results of the dose escalation phase of a phase I parmacokinetics, pharmacodynamic and biological activity study of ZD 1839: NCIC CTG IND. Proc Am Soc Clin Oncol 2001; 20:85a (Abstract #335).
95. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
96. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001; 40:297-306.
97. Swaisland H, Ramson M, Smith R, et al. Clinical drug interaction with ZD 1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy, male volunteers. Ann Oncol 2002; 13(suppl 5):27 (Abstract #97P).
98. Laight A, Swaisland HC, Partridge EA, et al. Metabolism of [14C]-ZD1839 in healthy male volunteers. Ann Oncol 2002; 13(suppl 5): 27 (Abstract #95P).
99. Harris A, Twelves C, White J, et al. A phase I trial assessing the pharmacokinetics and tolerability of ZD 1839 ('Iressa') in hepatically impaired patients with solid tumors. Eur J Cancer 2002; 38(suppl 7):S55 (Abstract #174).
100. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-124.
101. Giaccone G, Gonzalez-Larriba J, Smit E, et al. Combination therapy with gefitinib an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin, in patients with advanced solid tumors: promising preliminary results on tolerability, efficacy and pharmacokinetics. Ann Oncol 2004; 15:831-838.
102. Hammond A, Figueroa J, Schwartzberg L, et al. ZD 1839 (Iressa TM), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer (aCRC). Clin Cancer Res 2001; 7(suppl):S42 (Abstract #549).
103. Miller V, Johnson D, Heelan RT, et al. A pilot trial demonstrated the safety of ZD 1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:326a (Abstract #1301).
104. Goss G, Stewart D, Hirte H, et al. Initial results of part 2 of a phase I/II pharmacokinetics, pharmacodynamic and biological activity study of ZD 1839 (Iressa): NCIC CTG IND. 122. Proc Am Soc Clin Oncol 2002; 21:16a (Abstract #59).
105. De Bono JS, Hammond LA,Figueroa J, et al. Phase I/II trial of Iressa TM (ZD 1839) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer. Br J Cancer 2002; 86(suppl 1):S50 (Abstract #56).
106. Braun A, Dirsch O, Lindtner B, et al. Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD 1839 ('Iressa') and irinotecan (SN-38) in human colon tumor cells. Proc Am Soc Clin Oncol 2002; 21:83a (Abstract #329).
107. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
108. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-748.
109. Desai B, Higgins B, Smith M. Antitumor activity fo the EGFR/TK inhibitor TarcevaTM (erlotinib, OSI-774) in tumor models. Eur J Cancer 2002; 38(suppl):63 (Abstract #203).
110. Karp D, Ferrante D, Tensfeldt T, et al. A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors. Lung Cancer 2000; 29(suppl):65 (Abstract #208).
111. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
112. Hidalgo M, Rowinsky E, Miller A, et al. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 2001; 20:71a (Abstract #281).
113. Forouzesh B, Hidalgo M, Takimoto C, et al. Phase I pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 2002; 21:21a (Abstract #81).
114. Forero L, Hammond L, Tolcher A, et al. Phase I pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR)tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002; 21:25b (Abstract # 1908).
115. Ratain M, George C, Janish L, et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21:76b (Abstract #2115).
116. Finkler N, Gordon A, Crozier M, et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001; 20:208a (Abstract #831).
117. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinun-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
118. Senzer N, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001; 20:2a (Abstract #6).
119. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol 2001; 19:3154-3155.
120. Dent S, Zee B, Dancey J, et al. Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 2001; 19:785-791.
121. Eisenhauer EA, O'Dwyer PJ, Christian M, et al. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18:684-692.
122. Korn EL, Arbuck SG, Pluda JK et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19:265-272.
123. Solorzano CC, Jung YD, Bucana CD, et al. In vivo intracellular signaling as a market of antiangiogenic activity. Cancer Res 2001; 61:7048-7051.
124. Salh B, Marotta A, Matthewson C, et al. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 1999; 19:731-740.
125. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8:885-892.